| Sep 27 |
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
|
| Sep 5 |
Lexaria appoints Richard Christopher as CEO
|
| Sep 5 |
Lexaria Releases Strategic Letter from the Outgoing CEO
|
| Sep 5 |
Lexaria Welcomes Industry Veteran as New CEO
|
| Aug 29 |
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
|
| Aug 27 |
First Results from Lexaria's Second GLP-1 Human Pilot Study
|
| Aug 21 |
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
|
| Aug 19 |
Positive Results from Lexaria's Molecular Characterization Study
|
| Jul 23 |
LEXX: GLP-1 Agonist Program Updates
|
| Jul 18 |
Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations
|
